Company News: Page (1) of 1 - 05/12/14 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

Rockwell Medical, Inc. Reports First Quarter 2014 Results

(May 12, 2014)

WIXOM, Mich., May 12, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the first quarter ended March 31, 2014.



Q1 2014 Highlights




  • Sales were $13.0 million, a 5.1% increase over Q1 2013.


  • Gross profit was $1.7 million, a 31% increase over Q1 2013.


  • R&D expense was $4.6 million, a 64% decrease compared to $12.8 million in Q1 2013.


  • Cash and investments were $14.7 million as of March 31, 2014.



Q1 2014 Drug Development Highlights



  • Triferic New Drug Application submitted to FDA.


  • Triferic formulation patent issued for Japan.


  • Triferic long-term safety studies completed.


  • KOL breakfast meeting held in New York to examine anemia management and potential iron delivery advancements for CKD-HD patients.


  • Triferic clinical study abstracts and oral presentations accepted and presented at key nephrology conferences including the National Kidney Foundation Spring Clinical Meeting, Asia Pacific Congress on Nephrology and ISN Nexus Symposium.



For the quarter ended March 31, 2014, Rockwell reported a net loss of ($7.8) million or ($0.20) per share, which was a $7.6 million or 49% improvement compared to a net loss of ($15.4) million or ($0.72) per share in the first quarter of 2013. R&D expense decreased by $8.1 million compared to the first quarter of 2013.




"The submission of our Triferic NDA during the first quarter represents a major milestone for the Company," stated Mr. Robert L. Chioini, Founder, Chairman and CEO of Rockwell. "This NDA submission is the culmination of consistent, positive efficacy and safety results achieved across the entire Phase 3 Triferic clinical study program and it brings us much closer to the potential U.S. commercial launch of Triferic." Mr. Chioini continued, "R&D expense decreased significantly in the first quarter of 2014 as anticipated, and we expect a substantial decline each successive quarter during 2014."



Conference Call Information



Rockwell Medical will be hosting a conference call to review its first quarter 2014 results on Monday, May 12, 2014 at 4:30 pm ET. Investors are encouraged to call a few minutes in advance at (877) 383-7438, or for international callers (678) 894-3975, passcode # 43066158 or to listen to the call via webcast at the Rockwell Medical IR web page: http://ir.rockwellmed.com/



About Triferic



Triferic is a unique iron compound that is delivered to the hemodialysis patient via dialysate, replacing the 5-7 mg of iron that is lost during every dialysis treatment. Triferic is introduced into the sodium bicarbonate concentrate on-site at the dialysis clinic, which is subsequently mixed into dialysate. Once in the dialysate, Triferic crosses the dialyzer membrane and enters the blood where it immediately binds to apo-transferrin and is taken to the bone marrow to assist in new red blood cell formation, similar to how dietary iron is processed in the human body. In completed clinical trials to date, Triferic has demonstrated that it can safely and effectively deliver sufficient iron to the bone marrow, maintain hemoglobin and not increase iron stores (ferritin), while significantly reducing ESA dose.



About Rockwell Medical



Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.



Rockwell's lead drug candidate Triferic is in late-stage clinical development for the treatment of iron replacement in dialysis patients. Triferic delivers iron to the bone marrow of dialysis patients in a non-invasive, physiologic manner during their regular dialysis treatment, using dialysate as the delivery mechanism. In completed clinical trials to date, Triferic has demonstrated that it can safely and effectively deliver sufficient iron to the bone marrow, maintain hemoglobin and not increase iron stores (ferritin), while significantly reducing ESA dose. Triferic has completed the efficacy trials of its Phase 3 clinical study program (CRUISE-1 and CRUISE-2). Triferic is expected to address an estimated $600M U.S. market.



Rockwell is preparing to launch its FDA approved generic drug Calcitriol, to treat secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. Rockwell intends to launch Calcitriol once it receives FDA manufacturing approval, addressing an estimated $350M U.S. market.



Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell's products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell has three manufacturing/distribution facilities located in the U.S. and its operating infrastructure is a ready-made sales and distribution channel that is able to provide seamless integration into the commercial market for its drug products, Calcitriol and Triferic upon FDA market approval.



Rockwell's exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information. For a demonstration of the Triferic unique mechanism of action in delivering iron via dialysate, please view the animation video at http://www.rockwellmed.com/collateral/documents/english-us/mode-of-action.html.



Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell's intention to launch Calcitriol and Triferic® following FDA approval. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan", "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical's SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.



Triferic is a trademark of Rockwell Medical, Inc.







































































































































 

ROCKWELL MEDICAL, INC. AND SUBSIDIARY

 

CONSOLIDATED INCOME STATEMENTS

 

For the three months ended March 31, 2014 and March 31, 2013

 

(Unaudited)

 

 

 

 

Three Months

Three Months

 

Ended

Ended

 

 March 31, 2014

 March 31, 2013

Sales

$ 12,963,652

$ 12,336,374

Cost of Sales

11,283,694

11,055,394

Gross Profit

1,679,958

1,280,980

Selling, General and Administrative

4,090,199

3,916,783

Research and Product Development

 4,615,197

 12,754,518

Operating Income (Loss)

(7,025,438)

(15,390,321)

Interest and Investment Income, net

74,215

10,672

Interest Expense

 854,303

 75

Income (Loss) Before Income Taxes

(7,805,526)

(15,379,724)

Income Tax Expense

  --

  --

Net Income (Loss)

$ (7,805,526)

$ (15,379,724)

 

 

 

Basic Earnings (Loss) per Share 

($ 0.20)

($ 0.72)

 

 

 

 

 

 

Diluted Earnings (Loss) per Share 

($ 0.20)

($ 0.72)

 

 

 










































































































































































































 

ROCKWELL MEDICAL, INC. AND SUBSIDIARY

 

CONSOLIDATED BALANCE SHEETS

 

As of March 31, 2014 and December 31, 2013

 

(Unaudited)

 

 

March 31,

December 31,

ASSETS 

2014

 2013

Cash and Cash Equivalents

$ 661,117

$ 11,881,451

Investments Available for Sale

14,068,482

12,034,622

Accounts Receivable, net of a reserve of $41,000 in 2014 and $37,000 in 2013

4,100,453

4,578,319

Inventory

2,909,828

2,799,648

Other Current Assets

602,393

623,734

Total Current Assets

22,342,273

31,917,774

 

 

 

Property and Equipment, net

1,761,165

1,648,949

Intangible Assets

457,958

499,715

Goodwill

920,745

920,745

Other Non-current Assets

 1,311,411

 1,374,941

Total Assets

$ 26,793,552

$ 36,362,124

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

Note Payable Capitalized Lease Obligations

$ 4,113,013

$ 2,308,145

Accounts Payable

5,133,267

8,686,153

Accrued Liabilities

4,605,573

6,647,828

Customer Deposits

   244,314

   207,545

Total Current Liabilities

 14,096,167

 17,849,671

 

 

 

Long Term Debt

16,224,575

17,916,914

 

 

 

Shareholders' Equity:

 

 

Common Shares, no par value, 40,759,976 and 40,110,661 shares issued and outstanding

158,776,957

 154,457,878

Common Share Purchase Warrants, 838,071 and 983,071 warrants issued and outstanding 

4,225,669

 4,895,811

Accumulated Deficit

(166,596,095)

(158,790,569)

Accumulated Other Comprehensive Income

 66,279

 32,419

Total Shareholders' Equity (Deficit)

 (3,527,190)

 595,539

 

 

 

Total Liabilities And Shareholders' Equity

$ 26,793,552

 $ 36,362,124

 

 

 

























































































































































































































 

ROCKWELL MEDICAL, INC. AND SUBSIDIARY

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

For the three months ended March 31, 2014 and March 31, 2013

 

(Unaudited)

 

 

2014

2013

 

 

 

Cash Flows From Operating Activities:

 

 

Net (Loss)

$ (7,805,526)

$ (15,379,724)

Adjustments To Reconcile Net Loss To Net Cash Used In

 

 

Operating Activities:

 

 

Depreciation and Amortization

257,761

250,530

Share Based Compensation – Non-employee

--

966,227

Share Based Compensation- Employees

2,174,212

1,350,959

Amortization of Debt Issuance Costs

113,529

--

Non-Cash Interest Expense

112,529

--

Loss on Disposal of Assets

1,662

5,109

 

 

 

Changes in Assets and Liabilities:

 

 

Decrease (Increase) in Accounts Receivable

477,866

(30,367)

Increase in Inventory

(110,180)

(215,871)

Decrease (Increase) in Other Assets

(243,936)

257,464

Increase (Decrease) in Accounts Payable

(3,552,886)

1,266,909

Increase (Decrease) in Other Liabilities

  (1,790,208) 

 220,809

Changes in Assets and Liabilities

 (5,219,344)

  1,498,944

Cash Used In Operating Activities

 (10,365,177)

 (11,307,955)

 

 

 

Cash Flows From Investing Activities:

 

 

Purchase of Investments Available for Sale

(2,000,000)

--

Purchase of Equipment

 (329,882)

 (153,380)

Proceeds on Sale of Assets

 --

 5,998

Cash Used In Investing Activities

(2,329,882)

(147,382)

 

 

 

Cash Flows From Financing Activities:

 

 

Proceeds from the  Issuance of Common Shares and Purchase Warrants

 1,474,725

12,518,733

Payments on Notes Payable and Capital Lease Obligations

   --

  (829)

Cash Provided By Financing Activities

1,474,725

12,517,904

 

 

 

Increase (Decrease) In Cash

(11,220,334)

1,062,567

Cash At Beginning Of Period

11,881,451

4,711,730

Cash At End Of Period

$ 661,117

$ 5,774,297

 

 

 

CONTACT: Michael Rice, Investor Relations; 646-597-6979

Page: 1


Related Keywords: BIOTECHNOLOGY, MEDICAL, EARNINGSAnimators, Pro AV, Post/Production, Management, Management, Presentors, Management, Business Issues, Internet Media, Presentation, Channel/Distribution, Events, webcast, USA, Japan, Inc., Medicine, Diet, Disease, healthcare, Surgery, Science, Internet Technology, Medical, Other,


DMO TEXT LINKS
(Click here to place a textlink on this site)

Get 10 days of free unlimited access to lynda.com.
What do you want to learn today? Online video tutorials to help you learn software, creative, and business skills.
Click Here!


quad core
Lumia 530 4 GB White Smartphone - T-Mobile (1.2 GHz Quad-Core Processor, 512 MB RAM, 4 GB Internal Storage, Windows Phone 8.1, 4G, 5 MP Camera)
By Nokia, start from $ 49.00
Crystal 8 GB White Smartphone - Sprint (1.2 GHz Quad-Core Processor, 1.5 GB RAM, 8 GB Internal Storage, Android 4.4, 4G, 8 MP Camera)
By Sharp, start from $ 99.99
Moto X 16 GB Black Smartphone - Verizon Wireless 2014 Model (2.5 GHz Quad-Core Processor, 2 GB RAM, 16 GB Internal Storage, Android 5.0, 4G, 13 MP Camera)
By Motorola, start from $ 149.99
Ascend Mate2 Black Smartphone - Consumer Cellular (1.6 GHz Quad-Core Processor, 2 GB RAM, 16 GB Internal Storage, Android 4.3, 4G, 13 MP Camera)
By Huawei, start from $ 224.99
Galaxy Note 4 Black Smartphone - Verizon (2.7 GHz Quad-Core Processor, 3 GB RAM, 32 GB Internal Storage, Android 4.4, 4G, 16 MP Camera)
By Samsung, start from $ 149.99
Galaxy Note 4 32 GB White Smartphone - Verizon Wireless (2.7 GHz Quad-Core Processor, 3 GB RAM, 32 GB Internal Storage, Android 4.4, 4G, 16 MP Camera)
By Samsung, start from $ 149.99
HOT THREADS on DMN Forums
Content-type: text/html  Rss  Add to Google Reader or
Homepage    Add to My AOL  Add to Excite MIX  Subscribe in
NewsGator Online 
Real-Time - what users are saying - Right Now!

@ Copyright, 2014 Digital Media Online, All Rights Reserved